Sosei

Quick facts

Phase 2 pipeline

• AD 237 · Oncology
  AD 237 is a selective antagonist of the adenosine A2A receptor that blocks immunosuppressive signaling in the tumor microenvironment.
• AD 337 · Autoimmune diseases
  AD 337 is a small molecule targeting the S1P1 receptor.
• AD 452

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sosei portfolio CI brief
• Sosei pipeline updates RSS